Stay updated with breaking news from Mc Services. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
EQS-News: Newron Pharmaceuticals S.p.A. / Key word: Miscellaneous Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European... | March 28, 2023
Study 014/015 is a Phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) Full data suggest a new strategy for the management of TRS patients
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): Miscellaneous Newron presents six-month interim data from the first 100 patien...
EQS-News: Newron Pharmaceuticals S.p.A. / Key word(s): MiscellaneousNewron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry 28.03.2023 / 12:30 CET/CESTThe issuer is solely responsible for the content of this announcement.Newron presen...
Company also Provides Business Update and Outlook for 2023 - Conference Call and Webcast (in English) March 28, 2023, at 2:00 PM CEST/8:00 AM EDT THIS…